

In the Claims:

Please withdraw claims 3-6, 13-18 and 22-24 without prejudice. Please cancel claim 7. Please amend claims 1, 2, 8, 9, and 19-21.

1. (Currently amended) A method for detecting gastric cancer, comprising:
 - (a) providing a biological sample; and
 - (b) detecting over-expression of a cystatin SN ("CST1") protein or cystatin SN peptide having the sequence of SEQ ID NO:108 in said sample.
2. (Currently amended) The method of claim 1, further comprising detecting overexpression of a GTM family member protein selected from the group consisting of matrix metalloproteinase 12 (MMP12), inhibin ("INHBA"), insulin-like growth factor 7 ("IGFBP7"), gamma-glutamyl hydrolase ("GGH"), leucine proline-enriched proteoglycan ("LEPRE1"), cystatin S ("CST4"), secreted frizzled-related protein 4 ("SFRP4"), asporin ("ASPN"), cell growth regulator with EF hand domain 1 ("CGREF1"), kallikrein, tissue inhibitor of metalloproteinase 1 ("TIMP1"), secreted acidic cysteine-rich protein ("SPARC"), transforming growth factor ("TGFB1"), EGF-containing fibulin-like extracellular matrix protein 2 ("EFEMP2"), lumican ("LUM"), stannin ("SNN"), secreted phosphoprotein 1 ("SPP1"), chondroitin sulfate proteoglycan 2 ("CSPG2"), carboxypeptidase N ("CPN2"), N-acylsphingosine amidohydrolase ("ASAHI"), serine protease 11 ("PRSS11"), secreted frizzled-related protein 2 ("SFRP2"), phospholipase phospholipase A2, group XIIB ("PLA2G12B"), spondin 2 ("SPON2"), extracellular matrix protein ("SPON2"), olfactomedin 1 ("OLFM1"), thrombospondin repeat containing 1 ("TSRC1"), thrombospondin 2 ("THBS2"), adlican, cystatin SA ("CST2"), lysyl oxidase-like enzyme 2 ("LOXL2"), thyroglobulin ("TG"), transforming growth factor beta1 ("TGFB1"), transforming growth factor β induced protein ("TGFB-1"), serine or cysteine proteinase inhibitor clade H ("SERPINH1"), serine or cysteine proteinase inhibitor clade B ("SERPINB5"), matrix metalloproteinase 2 ("MMP2"), proprotein convertase subtilisin/kexin type 5 ("PCSK5"), kallikrein 10 ("KLK10"), hyaluronin and proteoglycan link protein 4 ("HAPLN4"), serine protease 11 ("PRSS11"), and transmembrane 6 superfamily member 2 ("TM6SF2").

3. (Withdrawn) The method of claim 2, wherein said step of detecting is carried out by detecting over-expression of GTM mRNA.
4. (Withdrawn) The method of claim 2, wherein said step of detecting is carried out by detecting over-expression of GMT cDNA.
5. (Withdrawn) The method of claim 4, wherein said step of detecting is carried out using an oligonucleotide complementary to at least a portion of said GMT cDNA.
6. (Withdrawn). The method of claim 4, wherein said step of detecting is carried out using qPCR method using a forward primer and a reverse primer.
7. (Canceled)
8. (Previously presented) The method of claim 1, wherein said step of detecting is carried out by detecting over expression of a cystatin SN peptide.
9. (Previously presented) The method of claim 8, wherein said step of detecting is carried out using an antibody directed against said cystatin SN peptide.
10. (Previously presented) The method of claim 9, wherein said step of detecting is carried out using a sandwich-type immunoassay method.
11. (Previously presented) The method of claim 9, wherein said antibody is a monoclonal antibody.
12. (Previously presented) The method of claim 9, wherein said antibody is a polyclonal antiserum.

13. (Withdrawn) A device for detecting a GTM, comprising:
 - a substrate having a GTM capture reagent thereon; and
 - a detector associated with said substrate, said detector capable of detecting a GTM associated with said capture reagent.
14. (Withdrawn) The device of claim 13, wherein said GTM capture reagent is an oligonucleotide.
15. (Withdrawn) The device of claim 13, wherein said GTM capture reagent is an antibody.
16. (Withdrawn) A kit for detecting cancer, comprising:
 - a substrate having a GTM capture reagent thereon;
 - a means for visualizing a complex of said GMT capture agent and a GMT;
 - reagents; and
 - instructions for use.
17. (Withdrawn) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific oligonucleotide.
18. (Withdrawn) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific antibody selective for a GTM-oligonucleotide, a GTM protein or a GTM peptide.
19. (Currently amended) A method for detecting gastric cancer, comprising the steps of:
 - providing a test sample from a patient suspected of having gastric cancer;
 - measuring the presence in said sample of a cystatin SN protein or a cystatin SN peptide having the sequence of SEQ ID NO:108 in said test sample; and
 - comparing the amount of GTM said cystatin SN protein or peptide present in said test sample with a value obtained from a sample from a subject not having gastric cancer.

20. (Currently amended) A method for screening for gastric cancer, comprising the steps of:
providing a test sample from a test subject;
measuring the presence of a cystatin SN protein or cystatin SN peptide having the sequence of SEQ ID NO:108 cystatin-SN in said test sample; and
comparing the amount of said cystatin SN protein or cystatin SN peptide present in said test sample with a value obtained from a control sample from a subject not having gastric cancer, and
finding overexpression of said cystatin SN protein or cystatin SN peptide in said test sample compared to said control sample.
21. (Currently amended) The method of claim 19, further comprising detecting overexpression of a GTM family member protein selected from the group consisting of ~~matrix~~ MMP12, INHBA, IGFBP7, GGH, LEPRE1, CST4, SFRP4, ASPN, CGREF1, ~~kallikrein~~ ("KLK10, TIMP1, SPARC, TGFB1, EFEMP2, LUM, SNN, SPP1, CSPG2, ASAHI, PRSS11, SFRP2, PLA2G12B, SPON2, OLFM1, TSRC1, THBS2, adlican, CST2, LOXL2, TG, TGFB1, SERPINH1, SERPINB5, MMP2, PCSK5 and TM6SF2.
22. (Withdrawn) The method of claim 19, wherein said GTM is an oligonucleotide specific for a GTM.
23. (Withdrawn) The method of claim 22, wherein said oligonucleotide is DNA.
24. (Withdrawn) The method of claim 22, wherein said oligonucleotide is RNA.
25. (Previously presented) The method of claim 19, wherein said step of measuring uses an ELISA assay.
26. (Previously presented) The method of claim 19, wherein said test sample is obtained from plasma.

27. (Previously presented) The method of claim 19, wherein said test sample is obtained from tissue, urine, gastric fluid, serum or stool.
28. (Previously presented) The method of claim 1, further comprising measuring overexpression of SERPINH1 or SERPINB5 in said sample.
29. (Previously presented) The method of claim 1, further comprising measuring overexpression of one or more of SFRP4, SFRP2, TSRC1, THBS2, LOXL2, SERPINH1, SERPINB5, and CGR11 in said sample.
30. (Currently amended) The method of claim 1, further comprising measuring overexpression of one or more proteins selected from the group consisting of adican, ASPN, CSPG2, cystatin SA ("CST2"), cystatin S ("CST4"), EFEMP2, GGH, INHBA, IGFBP7, LKL10, LEPRE1, LUM, LOXL2, MMP12, TIMP1, ASAHI, SPP1, SFRP2, SFRP4, CGR11, THBS2, SPARC, PRSS11, TG, and TGFB1 in said sample.

- 6 -

Attorney Docket No.: PEBL 1006 US1
PEBL/1006US1.104.Reply. 25 Nov.2009.doc

200.001:080103